| Name | Title | Contact Details |
|---|---|---|
Matthew Flack |
CISO | Profile |
Net Zero Since Day Zero. The ABB FIA Formula E World Championship brings dramatic racing to the heart of some of the worlds most iconic cities providing an elite motorsport platform for the worlds leading automotive manufacturers to accelerate electric vehicle innovation. The Formula E network of teams, manufacturers, partners, broadcasters, and host cities are united by a passion for the sport and belief in its potential to accelerate sustainable human progress and create a better future for people and planet.
Purem by Eberspächer is a global leader in exhaust technology and acoustic solutions, dedicated to advancing clean and quiet mobility for both passenger cars and commercial vehicles. As part of the Eberspächer Group, the company operates around 35 manufacturing sites and 40 development facilities across four continents, employing approximately 7,500 people, with a strong focus on exhaust technology. The company specializes in emission control products, including catalytic converters, particulate filters, and complete exhaust systems designed to reduce pollutants and meet global emissions standards. Additionally, Purem offers lightweight acoustic solutions to comply with noise regulations. With three R&D centers located in Germany, the USA, and China, the company is committed to innovation, holding around 2,000 patents and utilizing advanced development processes. Purem prioritizes sustainability through the use of lightweight materials and energy-efficient manufacturing practices, aligning with its vision of driving the mobility of tomorrow.
Segerstrom Center for the Arts is a leading performing arts complex located in Costa Mesa, California. Established in 1986 and renamed in 2011, it spans 14 acres and is recognized as Orange County’s largest non-profit arts organization. The Center features multiple venues, including Segerstrom Hall, Renée and Henry Segerstrom Concert Hall, Samueli Theater, and Judy Morr Theater, hosting a wide range of performances. The Center offers live performances that include Broadway shows, classical concerts, dance, and contemporary acts. It also provides venue rentals for private events and seminars, along with arts-based education programs through the Lawrence and Kristina Dodge Education Center. With a mission focused on artistic excellence and community engagement, the Center has welcomed over 20 million visitors and premiered over 60 world-class productions since its inception.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.